SignalCorporate
OmniAb outlines $35M-$39M 2026 revenue outlook, backed by Eli Lilly deal and xPloration doubling plan
OmniAb's $35M–$39M 2026 revenue outlook is backed by an Eli Lilly deal and xPloration doubling plan.
What changed
OmniAb's $35M–$39M 2026 revenue outlook is backed by an Eli Lilly deal and xPloration doubling plan.
Why it matters
OmniAb's $35M–$39M 2026 revenue outlook is backed by an Eli Lilly deal and xPloration doubling plan. — impact context not separately stored; see What changed.
← Dashboard
Oct 30, 2026 06:23 PM ET